Surgical Treatment for Recurrent Cholangiocarcinoma: a Single-center Series

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 May 5

PMID 37143948

Authors

Laura Fernandez

Mikel Gastaca

Eva Alonso

Mikel Prieto

Patricia Ruiz

Alberto Ventoso

Ibone Palomares

Arkaitz Perfecto

Andres Valdivieso

Affiliations

Soon will be listed here.

Abstract

Purpose: The present study aims to assess the results obtained after surgical treatment of cholangiocarcinoma (CC) recurrences.

Methods: We carried out a single-center retrospective study, including all patients with recurrence of CC. The primary outcome was patient survival after surgical treatment compared with chemotherapy or best supportive care. A multivariate analysis of variables affecting mortality after CC recurrence was performed.

Results: Eighteen patients were indicated surgery to treat CC recurrence. Severe postoperative complication rate was 27.8% with a 30-day mortality rate of 16.7%. Median survival after surgery was 15 months (range 0-50) with 1- and 3-year patient survival rates of 55.6% and 16.6%, respectively. Patient survival after surgery or CHT alone, was significantly better than receiving supportive care (p< 0.001). We found no significant difference in survival when comparing CHT alone and surgical treatment (p=0.113). Time to recurrence of <1 year, adjuvant CHT after resection of the primary tumor and undergoing surgery or CHT alone versus best supportive care were independent factors affecting mortality after CC recurrence in the multivariate analysis.

Conclusion: Surgery or CHT alone improved patient survival after CC recurrence compared to best supportive care. Surgical treatment did not improve patient survival compared to CHT alone.

References

Kang M, Jang J, Chang J, Shin Y, Lee D, Kim H . Actual Long-Term Survival Outcome of 403 Consecutive Patients with Hilar Cholangiocarcinoma. World J Surg. 2016; 40(10):2451-9. DOI: 10.1007/s00268-016-3551-9. View

Bartsch F, Paschold M, Baumgart J, Hoppe-Lotichius M, Heinrich S, Lang H . Surgical Resection for Recurrent Intrahepatic Cholangiocarcinoma. World J Surg. 2018; 43(4):1105-1116. DOI: 10.1007/s00268-018-04876-x. View

Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S . Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001; 8(2):154-7. DOI: 10.1007/s005340170039. View

Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt H . Surgery for cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1:143-155. PMC: 6563077. DOI: 10.1111/liv.14089. View

Primrose J, Fox R, Palmer D, Malik H, Prasad R, Mirza D . Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019; 20(5):663-673. DOI: 10.1016/S1470-2045(18)30915-X. View

Ercolani G, Vetrone G, Grazi G, Aramaki O, Cescon M, Ravaioli M . Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg. 2010; 252(1):107-14. DOI: 10.1097/SLA.0b013e3181e462e6. View

Kobayashi A, Miwa S, Nakata T, Miyagawa S . Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg. 2009; 97(1):56-64. DOI: 10.1002/bjs.6788. View

Dindo D, Demartines N, Clavien P . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240(2):205-13. PMC: 1360123. DOI: 10.1097/01.sla.0000133083.54934.ae. View

Kayahara M, Nagakawa T, Nakagawara H, Kitagawa H, Ohta T . Prognostic factors for gallbladder cancer in Japan. Ann Surg. 2008; 248(5):807-14. DOI: 10.1097/SLA.0b013e31818a1561. View

10.

Kamphues C, Seehofer D, Eisele R, Denecke T, Pratschke J, Neumann U . Recurrent intrahepatic cholangiocarcinoma: single-center experience using repeated hepatectomy and radiofrequency ablation. J Hepatobiliary Pancreat Sci. 2010; 17(4):509-15. DOI: 10.1007/s00534-009-0256-6. View

11.

Sakata J, Nomura T, Aono T, Kitami C, Yokoyama N, Minagawa M . Oncological outcomes of surgery for recurrent biliary tract cancer: who are the best candidates?. HPB (Oxford). 2021; 23(9):1371-1382. DOI: 10.1016/j.hpb.2021.01.007. View

12.

Saiura A, Yamamoto J, Kokudo N, Koga R, Seki M, Hiki N . Intrahepatic cholangiocarcinoma: analysis of 44 consecutive resected cases including 5 cases with repeat resections. Am J Surg. 2009; 201(2):203-8. DOI: 10.1016/j.amjsurg.2008.12.035. View

13.

Jung S, Woo S, Park H, Lee W, Han M, Han S . Patterns of initial disease recurrence after resection of biliary tract cancer. Oncology. 2012; 83(2):83-90. DOI: 10.1159/000339695. View

14.

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

15.

Bridgewater J, Galle P, Khan S, Llovet J, Park J, Patel T . Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60(6):1268-89. DOI: 10.1016/j.jhep.2014.01.021. View

16.

Nakeeb A, Pitt H, Sohn T, Coleman J, Abrams R, Piantadosi S . Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996; 224(4):463-73; discussion 473-5. PMC: 1235406. DOI: 10.1097/00000658-199610000-00005. View

17.

Si A, Li J, Xing X, Lei Z, Xia Y, Yan Z . Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: Factors associated with long-term outcomes. Surgery. 2016; 161(4):897-908. DOI: 10.1016/j.surg.2016.10.024. View

18.

Sano T, Shimada K, Sakamoto Y, Yamamoto J, Yamasaki S, Kosuge T . One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg. 2006; 244(2):240-7. PMC: 1602147. DOI: 10.1097/01.sla.0000217605.66519.38. View

19.

Krasnick B, Jin L, Davidson 4th J, Sanford D, Ethun C, Pawlik T . Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. J Surg Oncol. 2017; 117(3):363-371. PMC: 5924689. DOI: 10.1002/jso.24836. View

20.

Mansour J, Aloia T, Crane C, Heimbach J, Nagino M, Vauthey J . Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015; 17(8):691-9. PMC: 4527854. DOI: 10.1111/hpb.12450. View